While NMTs have been proposed to be potential anti-cancer targets, herein we demonstrate the potent pan-NMT inhibitor PCLX-001 [10–12] can efficiently target breast cancer by reducing the viability of numerous breast cancer cell lines in vitro and cause disease regression in vivo in an established murine xenograft breast cancer model. This evidence concerns the gene NMT1 and breast cancer.